RTOG 0929 A RANDOMIZED PHASE I/II STUDY OF ABT-888 IN COMBINATION WITH TEMOZOLOMIDE IN RECURRENT (TEMOZOLOMIDE RESISTANT) GLIOBLASTOMA

Objective

This is a clinical trial of ABT-888 which is investigational and will be administered by mouth. Temozolomide will also be used, which is approved by the FDA to treat glioblastoma and is administered by mouth.

IRB Protocol Number

11-0712

Principal Investigator(s)

DENISE M. DAMEK

Cancer Trials

• Brain and Nervous System Tumors

Sponsor(s)

RTOG

Contact

MONICA ROBISCHON at 720-848-0661
or MONICA.ROBISCHON@ucdenver.edu

Eligibility and Other Participant Information

What To Expect : A screening period to determine eligibility and a treatment period that can last as long as your study doctor determines you are benefiting from the treatment, and you are willing to continue participating. // Eligibility criteria include but are not limited to 18 years or older, with temozolomide resistant glioblastoma.